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ABSTRACT  
Zinc ion dependent β-lactamases (MBLs) catalyze the hydrolysis of almost all β-lactam 
antibiotics and resist the action of clinically available -lactamase inhibitors. We report how 
application of in silico fragment-based molecular design employing thiol-mediated metal 
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anchorage leads to potent MBL inhibitors. The new inhibitors manifest potent inhibition of 
clinically important B1 subfamily MBLs, including the widespread NDM-1, IMP-1 and VIM-2 
enzymes; with lower potency, some of them also inhibit clinically relevant Class A and D serine-
β-lactamases. The inhibitors show selectivity for bacterial MBL enzymes compared to human 
MBL fold nucleases. Co-crystallization of one inhibitor, which shows potentiation of 
meropenem activity against MBL-expressing Enterobacteriaceae, with VIM-2 reveals an 
unexpected binding mode, involving interactions with residues from conserved active site 
bordering loops.  
INTRODUCTION 
β-Lactam containing inhibitors remain the single most important antibacterials.1, 2 β-Lactams 
inhibit transpeptidases (or penicillin-binding proteins, PBPs) involved in cell wall biosynthesis 
by reacting with a catalytically crucial nucleophilic serine reside. Bacteria have developed 
multiple resistance mechanisms to β-lactams, most importantly by β-lactamase catalysed 
hydrolysis. There are four classes of β-lactamases:3 classes A, C, and D are serine-β-lactamases 
(SBLs), which are mechanistically related to the PBPs; class B are metallo-β-lactamases 
(MBLs), employing (a) zinc ion(s) in catalysis. 
Co-administration of a β-lactam antibacterial with a class A β-lactamase inhibitor (clavulanic 
acid,4 tazobactam,5 sulbactam) has successfully overcome some SBL-mediated resistance. 
Avibactam,6 a non β-lactam broader spectrum inhibitor of class A, C, and some class D SBLs, 
has recently been introduced into the clinic.7 As yet there are, however, no reports of clinically 
useful class B MBL inhibitors (Figure 1a).8-11 MBLs are a concern because they catalyze 
hydrolysis of almost all β-lactam antibacterials, including the carbapenems, which are commonly 
used for treatment of severe and highly resistant infections. MBLs are divided into the B1, B2, 
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and B3 subclasses based on metal site occupancy and sequence similarity.12-14 Subclass B1 
MBLs, which employ two zinc ions (Zn-1/Zn-2) are the most clinically relevant and include the 
New Delhi metallo-β-lactamase (NDM-1), Verona integron-encoded MBL (VIM), and 
Imipenemase (IMP) types of B1 MBLs. 
Combating increasing resistance mediated by MBLs requires the identification of either novel 
antibacterials or MBL resistant β-lactams (both likely substantial undertakings), or developing an 
MBL inhibitor for co-administration with an existing β-lactam. Here we report how the 
application of in silico fragment-based15, 16 molecular design led to identification of potent 
inhibitors of clinically relevant MBLs, some of which have (lower) activity against certain SBLs. 
The in silico studies employed a structure-guided approach in which fragments were anchored to 
the di zinc ion centre via a thiol and then optimised for binding via hydrophilic and electrostatic 
interactions. Whilst such metal anchorage (or 'support ligand') based approach has been applied 
in dynamic combinatorial based identification17 of ligands to MBLs, to our knowledge this is the 
first application of an in silico fragment-based approach for production of specific MBL 
inhibitors.  
 
RESULTS AND DISCUSSION 
De Novo Ligand Design  
The de novo molecular design program SPROUT15, 16 generates potential ligands via docking 
of fragments into targeted regions; subsequent user-directed assembly using template spacers to 
link these fragments together yields synthetically tractable scaffolds (Figure 1b). Analysis of an 
crystal structure of NDM-1 structure complexed with hydrolysed ampicillin (PDB code 3Q6X)14 
using SPROUT16 identified active site regions for targeting with in silico-generated fragments, 
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i.e. the regions proximal to: the Lys224 side chain, the Zn-2 metal ion, the nucleophilic 
hydroxide / water that “bridges” the two zinc ions, and a conserved tryptophan (Trp87) that 
makes hydrophobic interactions with the aromatic ampicillin C6 side chain18 (Figure 1c). 
Importantly, while details differ between individual MBLs, these features are predicted to be 
crucial for β-lactam binding by most, if not all, B1 MBLs.10 This design approach led to the 
identification of a simple benzyl thiol 1 (Figure 1) as a potential NDM-1 substrate-competitive 
inhibitor. A detailed, step-by step description of the in silico fragment based design novo design 
is given in the SPROUT utilizing design sections (Supporting Information). 
The in silico predicted interactions of 1 with NDM-1 include interaction between its 
carboxylate and the Lys224 side chain and the Zn-2 ion; anchoring of its thiol with both Zn-1 
and Zn-2; and between the aryl ring of 1 with Trp87, via π-stacking interactions (Figure 2a). 
Compound 1 was synthesized using Suzuki coupling (67%)19 of 5-bromophthalide and phenyl 
boronic acid to give a lactone which was ring-opened using Me3SiI to give the corresponding 
iodide (62%). Iodide displacement using thiourea, followed by hydrolysis gave 1 (81%; see 
Methods and Supporting Information for details).  
Using a fluorogenic MBL assay20 1 was then evaluated for inhibition of recombinant forms of 
NDM-1, IMP-1, and VIM-2. Inhibition studies with 1 and subsequent compounds were 
conducted in the presence of 0.01% Triton X-100 to reduce the potential of identifying protein 
aggregating compounds21-23. The results (Table 1) reveal 1 to be an inhibitor with sub-
micromolar IC50 values for all three of the tested B1 MBLs, with IC50 values 232 – 234 nM; 
these values compare favourably with the thiol-MBL inhibitors such as L-captopril for which 
IC50 values against B1 MBLs are in the micromolar range.
10  
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Crystallographic studies 
To investigate the binding of 1 with B1 MBLs, a structure of it complexed with VIM-2 was 
obtained by co-crystallization (1.74 Å resolution; space group C21; see Supporting Information, 
Figure S1 and Table S1). As predicted by the design studies, analysis of the crystal structure 
confirms that the thiol of 1 acts as a metal binding ligand that displaces the proposed ‘hydrolytic’ 
hydroxide ion bridging the two metal ions (Figure 2b). The crystallographically observed 
conformation of the biphenyl unit in VIM-2 was not, however, as predicted for NDM-1 (Figure 1 
and Figure 2a); unexpectedly, the aryl carboxylate of 1 is positioned to interact with Trp87 of 
VIM-2 and, via a water molecule, with Asp119, rather than with Arg228 (analogous to Lys 224 
in NDM-1) (Figure 2b). In the VIM-2 structure, 1 presents two binding faces, as also present in 
the predicted -lactam substrate, and observed hydrolysed -lactam, binding modes.10 One face 
is hydrophobic and interacts with the substantially hydrophobic L3 loop, via apparent π-stacking 
of the aryl ring of 1 with Tyr67 and interactions with Trp87 (Figure 2b). The other binding face 
of 1 involves electrostatic and hydrogen bonding interactions with residues from L10 loop, 
apparent interaction between the Arg228 guanidino group and the phenyl ring of 1 (3.8 Å), and 
potential interaction between one of the carboxylate oxygen’s of 1 with the side chain amide of 
Asn233 (3.6 Å). The difference in the predicted NDM-1 binding mode for 1 versus the 
crystallographically observed binding mode of 1 with VIM-2 may, in part, reflect the removal of 
water molecules from the NDM-1 structure prior to application of SPROUT to simplify the 
calculations, as well as active site differences between the wo enzymes15, 16 (see Supporting 
Information). 
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Structure Activity Relationship Studies 
Following the encouraging levels of inhibition observed with 1, we conducted structure 
activity relationship (SAR) studies. Modification of the terminal phenyl ring of 1 (Table 1) 
revealed no clear trend in potency when changing the electron density or steric bulk, via 
incorporation of bromine (17) or five-membered ring substituents (15 and 16), implying that the 
π-stacking interaction with Tyr67 is not crucial for affinity. Similarly, positioning substituents in 
the ortho-position of the phenyl ring (4, 9 and 10), to investigate whether changes to the dihedral 
angle between the aryl rings might affect affinity, did not yield substantial changes in potency. 
The importance of the spatial arrangement of functional groups was investigated via 19 
(Supporting Information, Figure S5) in which the methylene linking the thiol to the phenyl ring 
is switched to link the carboxylic acid. The thiolactone 18, (Supporting Information, Figure S4) 
was synthesised to test whether it undergoes hydrolysis to 1 (Supporting Information, Table S2). 
Neither 18 nor 19 manifested significant activity against VIM-2 (IC50 > 100 μM) showing that 
the arrangement of the functional groups is important and indicating that the thiolactone 18 does 
not appear to be an efficient substrate for VIM-2. 
2-17 were evaluated for inhibition against NDM-1 and IMP-1 (Table 1 and Supporting 
Information, Table S2); selected compounds (4-8) were screened against the model MBL BcII 
and the ‘hybrid’ B1/B2 like MBL SPM-1.24 The results reveal 4-8 to be active against BcII and 
SPM-1, with IC50 values 0.78 – 7.8 μM (Supporting Information, Table S3). Moreover, except 
for 11, all compounds manifested sub-micromolar IC50 values against IMP-1 with several 
compounds showing sub-micromolar activity against NDM-1 (5, 6, 7, 8 and 13). Binding of 
selected inhibitors to VIM-2 and NDM-1 was investigated by NMR:25, 26 The 1H CPMG NMR 
results validated25 binding of 1 and 9 to VIM-2 and 19F NMR26 was used to validate binding to 
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NDM-1 (Supporting Information, Figure S7). Consistent with the inhibition data, the NMR 
analyses show that 1 and 9 bind with KD values < 1 μM to VIM-2 and 9 out competes 11 for 
binding to NDM-1 (Supporting Information, Figure S8). 
In the initial assessment of our inhibitors as hits we screened 4 and 9 against the SBL AmpC21;  4 
and 9 showed activity against AmpC both in the presence and absence of Triton X-100 
(Supplementary Information, Table S4). We then screened 1, 7, 8 and 9 against TEM-1, AmpC, 
and OXA-10, which are representatives of Class A, C, and D SBLs, respectively (Supporting 
Information, Table S4). Interestingly, 8 and 9 inhibited TEM-1 and 9 inhibited OXA-10 (IC50s 
32.8, 5.5 and 37.3 µM, respectively, Supporting Information, Table S4). Although we have been 
unable to obtain structures of these compounds complexed with SBLs, these results show some 
of the inhibitors could interact with both SBLs and MBLs via related binding modes as shown in 
Figure 2); indeed, our predicted binding mode of 1 to TEM-1 and OXA-10 is similar to that 
observed crystallographically for a recently identified biphenyl carboxylic acid obtained through 
a surface plasmon resonance (SPR) based screen for inhibitors of the OXA-48 SBL27. However, 
the unexpected crystallographically observed binding mode of 1 to VIM-2 (Figure 2) means 
caution should be exercised in predicting the SBL binding modes of our compounds. 
 
Selectivity screening 
Clinically relevant MBL inhibitors should show selectivity towards the bacterial MBLs over 
human metallo-enzymes, including human MBL-fold enzymes.28 We tested 1, 5, 13 and 17 
against two human MBL fold enzymes involved in DNA repair, DNA cross-link repair enzymes 
1A and B (DCLRE1A and DCLRE1B). DCLRE1A was only weakly inhibited by 1 (IC50 247 ± 
154 µM) and DCLRE1B was inhibited by 1, 5 and 17 (IC50s 149 ± 27, 268 ±112 and 185 ± 50 
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µM, respectively), implying, at least partial, selectivity of the compounds towards the bacterial 
MBLs. Compound 1 showed good aqueous solubility and underwent moderate metabolism in 
human liver microsomes (see Supporting Information). 
 
Antibacterial Activity 
Compounds 1 and 11-17 were screened in minimal inhibitory concentration (MIC) 
antimicrobial assays, in co-administration studies with the clinically important carbapenem 
meropenem, using MBL producing strains of E. coli and K. pneumoniae (species where NDM-1 
production is a growing clinical problem).29 Tests in the absence of inhibitors manifested 
meropenem MICs against MBL-producing bacteria of >128 μg/ml, and that when tested alone 1 
has no antibacterial activity within limits of detection (Table 2). Encouragingly, at 100 μg/ml all 
tested compounds, apart from 11, reduced the MIC of meropenem against NDM-1-producing 
strains. Compound 16 showed the strongest activity, reducing the meropenem MIC to 8 μg/ml 
against K. pneumoniae. 
 
CONCLUSIONS  
Overall, the results reveal how computer aided design can help generate broad spectrum MBL 
inhibitors active against three types of clinically important B1 MBLs, as well as some SBLs. The 
inhibitors can reduce MICs of meropenem against MBL-producing bacteria, indicating they are 
suitable for further development. Unlike some reported MBL inhibitors,30 our compounds bind 
directly to the MBL active sites, i.e. do not function by removing the zinc ions, as shown by 
NMR and crystallographic analyses.31 While utilizing its thiol to bind the MBL active site by 
intercalating between the two B1 MBL subclass zinc ions has precedent,8 the 
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crystallographically observed mode of binding 1 with VIM-2 (Figure 1), has not been previously 
observed. The difference between the crystallographically observed binding mode for 1 with 
VIM-2 and that predicted for NDM-1 (Figure 2) indicates how differences in closely related 
metallo-enzymes can apparently enable different binding modes of the same inhibitors, even 
when they are anchored in the same manner, i.e. to the two active site zinc ions of the B1 MBLs. 
It may also reflect of limitations in our current computational methodology, including with an 
inability to deal with solvation. 
The observation of activity for the designed compounds against several different types of 
clinically relevant B1 MBLs is notable (Table 1) because inhibition of a spectrum of MBLs is a 
likely prerequisite for clinical application of an MBL inhibitor. Although the compounds 
described here are unlikely to be of direct clinical utility, the work suggests that computational 
chemistry can have an important role in designing inhibitors that are active for use against both 
current and future predicted antibacterial resistance mediated by -lactamases. The need for an 
ability to rapidly optimise against emerging resistance is highlighted by the identifications of the 
multiple class B1 MBL variants already identified.12 Our approach may have utility in efficiently 
identifying other inhibitor chemotypes involving alternative metal-coordinating moieties, as well 
as inhibitors not relying on metal coordination. 
 
EXPERIMENTAL SECTION 
The Supporting Information contains a complete general experimental section, including all 
procedures and equipment used. Chemicals were from commonly used suppliers (Aldrich, Acros, 
and Alfa Aesar) and used without purification. The purity of compounds submitted for screening 
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was ≥95% as determined by UV analysis of liquid chromatography (HPLC) chromatograms at 
254 nM.  
General procedure for the Suzuki cross coupling reaction 
The boronic acid (1.1 equiv.) was added to a stirred solution of 5-bromophthalide (1.0 equiv.), 
potassium carbonate (1.0 equiv.) and tetrakis(triphenylphosphine) palladium (0) (0.05 equiv.) in 
THF (4 mL) and water (2 mL). The reaction mixture was heated at reflux for 12 h, then filtered 
through Celite®, and concentrated in vacuo. The residue was diluted with water (20 mL), then 
extracted using dichloromethane (3 × 20 mL). The combined organic extracts were dried 
(MgSO4) and concentrated in vacuo to give a pale-yellow solid, which was purified using flash 
column chromatography to afford the coupled product. 
General procedure for lactone opening with iodotrimethylsilane forming the iodides 
The benzofuranone (1.0 equiv.) was dissolved in dichloromethane (4.5 mL); TMSI (1.5 equiv.) 
was then added and the reaction was refluxed under nitrogen for 3 h. After this time, the mixture 
was cooled to room temperature and quenched with water (3 mL). The precipitate was isolated 
by filtration washing with water (2 × 10 mL) to give the desired iodide product as an off-white 
solid, which was used without further purification.  
General procedure for introduction of the thiol32 
A mixture of thiourea (1.1 equiv.) in THF (3 mL) was heated to reflux. To this mixture was 
added the iodide product of the previous procedure (1.0 equiv.). The reaction mixture was heated 
at reflux for 16 h under nitrogen. The reaction mixture was then cooled to room temperature and 
concentrated in vacuo. The residue was re-suspended in 2M aqueous NaOH (5 mL) and the 
solution refluxed for 3 h. The reaction mixture then acidified with 2M aqueous HCl to ~pH2. 
The colorless precipitate was isolated by filtration.  
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Representative synthesis: for compound 1 
Synthesis of 5-phenyl-1,3-dihydo-2-benzofuranone 
Phenyl boronic acid (0.32 g, 2.58 mmol, 1.1 equiv.) was added to a stirred solution of 5-
bromophthalide (0.50 g, 2.35 mmol, 1.0 equiv.), potassium carbonate (0.33 g, 2.35 mmol, 1.0 
equiv.) and tetrakis(triphenylphosphine) palladium (0) (0.14 g, 0.12 mmol, 0.05 equiv.) in THF 
(4 mL) and water (2 mL). The reaction mixture was heated to reflux for 12 h, then filtered 
through Celite®, and concentrated in vacuo. The residue was diluted with water (20 mL) and 
extracted using dichloromethane (3 × 20 mL). The combined organic extracts were dried 
(MgSO4), then concentrated in vacuo to give a pale-yellow solid, which was purified by flash 
column chromatography to afford the desired product as a cream colored solid, which was used 
without further purification. (0.33 g, 1.58 mmol, 67%) m.p.: 124.4-125.8 °C; Rf: 0.5 (2:1 petrol-
EtOAc); δH (300 MHz, CDCl3): 7.98 (1H, d, J 7.6, 3-H), 7.75 (1H, d, J 7.6, 4-H), 7.68 (1H, s, 6-
H), 7.62 (2H, d, J 7.1, 2’-H and 6’-H), 7.47 (2H, app. t, J 7.1, 3’-H and 5’-H) 7.45 (1H, t, J 7.1, 
4’-H),  5.38 (2H, s, CH2O); δC (75 MHz, CDCl3): 147.5 (C=O), 147.3 (C1), 139.6 (C3), 129.1 
(C3’’ and C5’), 128.6 (C2), 128.5 (C5),127.5 (C2’ and C6’) 126.1 (C4’), 124.5 (C1’), 120.6 
(C6),  69.9 (CH2O); νmax/ cm-1 (solid): 3473, 3070, 2924, 1747, 1615, 1452; HPLC: Tr= 3.00 
(100% rel. area); m/z (ES): (Found: MNa+, 233.0573. C14H10O2 requires MNa, 223.0570). 
 
Synthesis of 2-iodomethyl-4-phenyl-benzoic acid 
5-Phenyl-1,3-dihydo-2-benzofuranone (0.20 g, 0.95 mmol, 1.0 equiv.) was dissolved in 
dichloromethane (4.5 mL). TMSI (0.20 mL, 1.43 mmol, 1.5 equiv.) was added and the reaction 
was refluxed under nitrogen for 3 h. The mixture was then cooled to room temperature and 
quenched with water (3 mL). The precipitate was isolated by filtration, washing with water (2 × 
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10 mL) to give the desired product as a pale brown solid, which was used without further 
purification. (0.20 g, 0.59 mmol, 62%) m.p.: 81.3-82.4 °C; Rf: 0.75 (CHCl3); δH (300MHz, 
DMSO-d6): 7.94 (1H, d, J 8.3, 6-H), 7.88 (1h, d, J 1.8, 3-H), 7.73 (2H, d, J 7.3, 6’-H and 2’-H), 
7.68 (1H, dd, J 8.3 and 1.8, 5-H), 7.51 (2H, app. t, J 7.3, 5’-H and 3’-H), 7.44 (1H, t, J 7.3, 4’-H), 
5.09 (2H, s, CH2); νmax/ cm-1 (solid): 2806, 2630, 1750, 1603, 1257, 909; m/z (ES): (Found: 
[M+2Na-H]+, 382.9516. C14H11IO2 requires [M+2Na-H], 382.9515). 
 
Synthesis of 4-phenyl-2-sulfonylmethylbenzoic acid (1) 
A mixture of thiourea (0.16 g, 2.11 mmol, 1.1 equiv.) and 2-Iodomethyl-4-phenyl-benzoic acid 
(0.65 g, 1.92 mmol, 1.0 equiv.) in THF was heated  at reflux for 16 h under an atmosphere of 
nitrogen, then  cooled to room temperature. The mixture was then concentrated in vacuo, then re-
suspended in 2M aqueous NaOH (5 mL) and refluxed for 3 h. The resultant mixture then 
acidified with 2M aqueous HCl to ~pH2. The pale yellow microcrystals were isolated by 
filtration. C14H10Cl2O2S requires [M-H], 310.9706). (0.25 g, 1.01 mmol, 53%). m.p.: 168.2-
169.9 °C; Rf: 0.20 (19:1 DCM−MeOH); δH (300 MHz, DMSO-d6): 7.95 (1H, d, J 8.2, 6-H), 
7.77 (1H, d, J 2.0, 3-H), 7.73 (2H, d, J 7.4, 6’-H and 2’-H), 7.65 (1H, dd, J 8.2 and 2.0, 5-H), 
7.52 (2H, app. t, J 7.4, 5’-H and 3’-H), 7.44 (1H, t, J 7.4, 4’-H), 4.13 (2H, d, J 8.5, CH2), 2.87 
(1H, t, J 8.5, SH);  δC (75 MHz, DMSO-d6): 168.0 (C=O), 144.3 (C4), 143.6 (C1’), 138.7 (C2), 
131.5 (C6), 129.0 (C5’ and C3’), 128.9 (C4’), 128.2 (C5), 127.8 (C1), 126.9 (C6’ and C2’), 
124.9 (C3), 26.4 (CH2); νmax/ cm-1 (solid): 2976, 1681, 1350, 1278, 756; HPLC: Tr= 2.88 
(95% rel. area); m/z (ES): (Found: [M-H]-, 243.0477 C14H12O2S requires [M-H], 243.0485). 
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Figure 1. Design of broad spectrum MBL inhibitors. A) Known MBL binders (inhibitors) and 
compound 1.8-11 B) Key elements used in the SPROUT computational design process leading to 
the identification of putative broad spectrum MBL inhibitors. C) Outline mechanism for SBLs 
and MBLs as shown for a penicillin substrate. 
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Figure 2. Predicted potential binding modes for the designed NDM-1 inhibitors and the 
crystallographically observed binding mode for VIM-2. (A), (C), and (D) shows views from 
modelling of 1 into the active sites of NDM-1, TEM-1, and OXA-10, respectively (see 
Supporting Information for details); (B) shows view from a crystal structure of 2 co-crystalized 
with VIM-2 (PDB ID: 5K48).  
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Table 1. IC50
 values of de novo designed thiols against clinically relevant B1 MBLs. Assays 
were conducted as reported20. 
 
 
No. X cLogPa IC50 NDM-1 
(µM) 
IC50 VIM-2 
(μM) 
IC50 IMP-1 
(μM) 
1 C6H5 3.76 5.59 ± 0.05 0.23 ± 0.04 0.23 ± 0.04 
4 2-ClC6H4 4.37 2.85 ± 0.03 0.18 ± 0.09 0.30 ± 0.06 
5 3-ClC6H4 4.37 0.31 ± 0.05 0.07 ± 0.05 0.14 ± 0.05  
6 4-ClC6H4 4.37 0.42 ± 0.02 0.10 ± 0.03 0.06 ± 0.05 
7 3-FC6H4 3.90 0.59 ± 0.02 0.20 ± 0.06 0.39 ± 0.08  
8 4-FC6H4 3.90 0.71 ± 0.01 0.23 ± 0.03 0.30 ± 0.09 
9 2,3-ClC6H3 4.97 1.16 ± 0.05 0.04 ± 0.03 0.37 ± 0.06 
10 2-CF3C6H4 4.64 8.82 ± 0.05 0.15 ± 0.08 0.48 ± 0.04 
11 3,5-CF3C6H3 5.52 43.95 ± 0.06 0.45 ± 0.07 1.72 ± 0.04 
12 2-Naphthyl 4.75 2.42 ±0.03 0.07 ± 0.03 0.22 ± 0.03 
13 4-EtC6H4 4.72 0.57 ± 0.02 0.10 ± 0.03 0.05 ± 0.03 
14 3-EtO-C6H4 3.96 7.59 ± 0.03 0.18 ± 0.16 0.32 ± 0.03 
15 2-Furyl 2.82 10.21 ± 0.04 0.36 ± 0.02  0.39 ± 0.03 
16 3-Thienyl 3.54 6.78 ± 0.09 0.17 ± 0.12 0.18 ± 0.04 
17 Br 2.88 > 100 0.17 ± 0.01 0.80 ± 0.03 
acLogP values were calculated using MarvinSketch 17.28 (ChemAxon).   
b The IC50 values are shown as the mean ± SD from minimum three separate experiments. 
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Table 2. Determination of Meropenem MICs against bacterial strains when co-administered with 
the designed β-lactamase inhibitors. Assays were conducted as reported11. 
Compound 
Number 
X Meropenem MIC (μg/mL) 
NDM-1 producing K. 
pneumoniae (ATCC 5055) 
Meropenem MIC (μg/mL) 
NDM-1 producing E. coli 
(MG1655) 
Meropenem  > 128 > 128 
1 C6H5 32 16 
17 Br 64 32 
11 3,5-CF3C6H3 >128 >128 
12 2-Naphthyl 32 32 
13 4-Et-C6H4 64 32 
14 3-EtO-tC6H4 16 64 
15 2-Furyl 64 32 
16 3-Thienyl 8 16 
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